Steven Paul Delco
Delco worked in the life sciences industry for over twenty years and then as a Wall Street analyst and PM for over ten years. Most recently, he was principal portfolio manager in Health at Weiss Peck & Greer/ROBECO where he achieved a 33% return in healthcare for 2005 and returned a composite performance of over 52% with his original long/short SWAP baskets approach GSRODELC/GSROBIOT. While at Weiss Peck, as a consultant between 2005-2007 Delco founded a very important antibiotics biotech company (BioRelix) out of Dr. Ronald Breaker’s ground breaking riboswitch technology—recently closing a $25 million A round of financing with top VCs. He was also vice president and the senior biotech analyst at Natexis Bleichroeder where he led their biotech team. Prior to NB, Steven was with The Fortis Group as the senior biotech analyst and managing director where he created and managed a global biotech research team spanning Amsterdam, Paris and New York. In 1997, Delco started his Wall Street career at Miller Tabak + Co. LLC prior to founding a successful biotech newsletter that gained him notice on Wall Street. At MT, he built and headed the biotech research team. The Carson Groupranked him as the number one biotech analyst in 1999 due to stock picking performance that achieved a 294% return that year. Delco has also trained some of the leading analysts and portfolio managers on Wall Street.
Steven graduated from Fairfield University with a degree in biochemistry in 1974 and then completed doctoral graduate course work in immunochemistry and biochemistry at the University of Minnesota (ABD). In 1980, Steven joined the biotech company American Cytocorp, Inc., as Director of product development and marketing. This company was one of the first to explore contract manufacturing of MAb. In 1982 he founded and was president of Delco Scientific Resources, Inc (DSR). DSR, Inc. was a market research / market and product development consulting firm that specialized in biotechnology, biomedical and pharmaceutical products and instrumentation. Upon the sale of DSR, Inc., in 1994 to Dunn and Bradstreet, Steven joined the manufacturer of imaging and raman spectrometers, Chromex, Inc. as President and COO. Steven’s insights led to 10% increase in overall gross margins, a 29% increase in instrument gross margins and a 16% increase in overall sales. In 1996, Steven founded Biovest, a biotech newsletter for which he served as publisher and consultant. He gained international recognition and had studies reported in the Wall Street Journal, Bloomberg Online, and Reuters among others. In addition, Steven has had teaching and research appointments at Sloan-Kettering Institute for Cancer Research, University of Minnesota, and City University of New York.

Delco Advisors Assets


-Key relationships with international  institutional investors


-International reputation in bringing exceptional investment ideas to Institutional investors.


-Relationships with many key biotechnology and pharmaceutical CEO’s


-Extensive expertise as a top ranked analyst and portfolio manager in healthcare


-Presence in Europe with office based in Amsterdam, The Netherlands.